Biolife Solutions Inc (BLFS) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket
 


Biolife Solutions Inc   (NASDAQ: BLFS)


Biolife Solutions Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Biolife Solutions Inc's ROI in the second quarter of 2026?
Biolife Solutions Inc achieved a return on average invested assets (ROI) of 14.83 % in its second quarter of 2026, this is above BLFS's average return on investment of -22.91%.
Biolife Solutions Inc invested over the 12 months ending in its second quarter of 2026 $391 million

ROI has improved compared to -0.8% in the first quarter of 2026, due to net income growth.

Within the Healthcare sector 69 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 1667 to 2601.

Definition and Formula of Return on Investment



Return On Investment (Jun 30 2026)
II. Quarter
(Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
(Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 8.42 % 4.31 % 3.57 % 1.31 % -1.07 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 434 383 383 365 359
Return On Investment (TTM) 14.83 % -0.8 % -1.25 % -0.88 % -1.53 %
BLFS's Overall Ranking # 2601 # 1667 # 1967 # 2456 # 2365
Seq. Investment Change TTM 5.01 % 1.03 % 1.11 % 1.07 % 1.03 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions 58 -3 -5 -3 -6




Return On Investment BLFS's Ranking
Within: No.
Industry # 16
Sector # 70
Overall # 2601

Return On Investment Statistics
High Average Low
23.04 %
-22.91 %
-95.62 %
(Mar 31 2020)   (Mar 31 2017)







Financial Statements
Biolife Solutions Inc's II. Quarter Investments $ 434 Millions BLFS's Balance sheet
Biolife Solutions Inc's II. Quarter Income $ 45 Millions Quarterly BLFS's Income Statement
BLFS's Income by Division See BLFS's Income by Division


BLFS Annual Return On Investment (Dec 31 2025)
2025
(Dec 31 2024)
2024
(Dec 31 2023)
2023
(Dec 31 2022)
2022
(Dec 31 2021)
2021
Total Investments in Millions 383 367 371 406 514
Y / Y Investment Growth 4.4 % -1.02 % -8.66 % -21.03 % 134.28 %
Net Income in Millions -5 -20 -66 -140 -8
Y / Y Net Income Growth - - - - -
Annual Return On Investment -1.2 % -5.5 % -17.93 % -34.46 % -1.49 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Medical Equipment & Supplies Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
BLFS's Roi Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for BLFS's Competitors
Subscribers only: Roi for Biolife Solutions Inc's Suppliers
Subscribers only: Return On Investment for BLFS's Customers

Other Ratios
BLFS's Roa BLFS's Inventory Turnover Ratio BLFS's Growth Rates BLFS's Dividend Statistics
BLFS's Profitability Ratios BLFS's Asset Turnover Ratio BLFS's Dividend Growth
BLFS's Roe BLFS's Valuation Ratios BLFS's Financial Strength Ratios BLFS's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI
Tg Therapeutics Inc   39.26 %
Medpace Holdings Inc   35.54 %
Mettler toledo International Inc   34.41 %
Eli Lilly And Company  33.95 %
Acadia Pharmaceuticals Inc   31.05 %
Caredx Inc   29.42 %
Adma Biologics Inc   28.94 %
Protalix Biotherapeutics inc   25.72 %
Pro dex Inc   24.29 %
Innoviva Inc   23.33 %
Electromed Inc   23.18 %
Zevra Therapeutics Inc   22.90 %
Iradimed Corporation  22.57 %
Alnylam Pharmaceuticals Inc   22.10 %
Eton Pharmaceuticals Inc   21.31 %
Dexcom Inc   20.98 %
Healthcare Services Group Inc   20.93 %
Arcutis Biotherapeutics Inc   20.77 %
Chemed Corporation  20.13 %
Resmed Inc   20.01 %
Halozyme Therapeutics Inc   19.99 %
Vertex Pharmaceuticals Inc  19.97 %
Agilent Technologies inc   19.84 %
Illumina Inc   19.61 %
Puma Biotechnology Inc   19.60 %
United Therapeutics Corporation  19.53 %
Zoetis Inc   19.44 %
Krystal Biotech Inc   19.16 %
Carlisle Companies Incorporated  18.88 %
Neurocrine Biosciences Inc   17.51 %


Date modified: 2026-09-08T16:49:20+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.